Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-08-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-3093PMID 17699868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.

  2006cited by this paper
• International Union of Pharmacology. LXIV. Estrogen Receptors

  2006cited by this paper
• Estrogen carcinogenesis in breast cancer.

  2006cited by this paper
• Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.

  2006cited by this paper
• Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.

  2006cited by this paper
• Basic research for hormone-sensitivity of breast cancer

  2006cited by this paper
• Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches

  2006cited by this paper
• HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.

  2005cited by this paper
• Regulation of the Dynamics of hsp90 Action on the Glucocorticoid Receptor by Acetylation/Deacetylation of the Chaperone*

  2005cited by this paper
• Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

  2005cited by this paper
• Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

  2005cited by this paper
• Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

  2005cited by this paper
• Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.

  2005cited by this paper
• Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2

  2005cited by this paper
• Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.

  2005cited by this paper
• Estrogen receptor α and β subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells ☆

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.

  2005cited by this paper
• Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor α-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines

  2004cited by this paper
• Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.

  2004cited by this paper
• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  2004cited by this paper
• Hsp90: an emerging target for breast cancer therapy

  2004cited by this paper
• Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.

  2003cited by this paper
• Class II histone deacetylases: versatile regulators.

  2003cited by this paper
• Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation*

  2003cited by this paper
• Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway

  2003cited by this paper
• Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor.

  2003cited by this paper
• Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

  2003cited by this paper
• Estrogen receptor phosphorylation.

  2003cited by this paper
• Genetic Dissection of p23, an Hsp90 Cochaperone, Reveals a Distinct Surface Involved in Estrogen Receptor Signaling*

  2003cited by this paper
• Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90.

  2002cited by this paper
• Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators

  2002cited by this paper
• Cellular functions of plasma membrane estrogen receptors.

  2002cited by this paper
• HDAC6 is a microtubule-associated deacetylase

  2002cited by this paper
• Connections and Regulation of the Human Estrogen Receptor

  2002cited by this paper
• Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression*

  2002cited by this paper
• Heat Shock Protein 90 Is a Rational Molecular Target in Breast Cancer

  2002cited by this paper
• Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression.

  2002cited by this paper
• Combinatorial control of gene expression by nuclear receptors and coregulators.

  2002cited by this paper
• Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

  2001cited by this paper
• Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.

  2001cited by this paper
• Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells

  2001cited by this paper
• Control of estrogen receptor ligand binding by Hsp90.

  2000cited by this paper
• Estrogen receptor interaction with co-activators and co-repressors.

  2000cited by this paper
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Role for Akt in Mediating the Estrogenic Functions of Epidermal Growth Factor and Insulin-Like Growth Factor I*

  2000cited by this paper
• Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.

  1999cited by this paper
• Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.

  1994cited by this paper

• CoREST in pieces: Dismantling the CoREST complex for cancer therapy and beyond

  2025cites this paper
• Augmented Global Protein Acetylation Diminishes Cell Growth and Migration of Cholangiocarcinoma Cells

  2024cites this paper
• Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer.

  2024cites this paper
• Envisioning Clinical Management of Breast Cancer: a Comprehensive Review.

  2024cites this paper
• Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

  2023cites this paper
• Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA

  2023cites this paper
• Short chain fatty acids exhibit selective estrogen receptor downregulator (SERD) activity in breast cancer.

  2022cites this paper
• B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.

  2022cites this paper
• Enhancing progestin therapy via HDAC inhibitors in endometrial cancer.

  2022cites this paper
• MOF negatively regulates estrogen receptor α signaling via CUL4B-mediated protein degradation in breast cancer

  2022influential citation
• Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer

  2022cites this paper
• Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer.

  2021cites this paper
• Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

  2021cites this paper
• Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90

  2021cites this paper
• Vorinostat (SAHA) and Breast Cancer: An Overview

  2021cites this paper
• A Genome-Edited ERα-HiBiT Fusion Reporter Cell Line for the Identification of ERα Modulators Via High-Throughput Screening and CETSA

  2021cites this paper
• Heat shock factor 1 (HSF1) cooperates with estrogen receptor α (ERα) in the regulation of estrogen action in breast cancer cells

  2021cites this paper
• Simvastatin-romidepsin combination kills bladder cancer cells synergistically

  2020cites this paper
• A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot–Marie–Tooth disease type 1A

  2020cites this paper
• Post-translational modifications of Hsp90 and translating the chaperone code

  2020cites this paper
• Histone Deacetylation

  2020cites this paper
• The Major Capsid Protein, VP1, of the Mouse Polyomavirus Stimulates the Activity of Tubulin Acetyltransferase 1 by Microtubule Stabilization

  2020cites this paper
• Present and future perspectives for targeting histone modifications in therapy

  2020cites this paper
• Targeting hsp90 family members: A strategy to improve cancer cell death.

  2019cites this paper
• The application of the improved 3D rat testicular cells co-culture model on the in vitro toxicity research of HZ1006

  2019cites this paper
• Role of the Post-translational Modifications of HSP60 in Disease

  2019cites this paper
• Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents.

  2019cites this paper
• Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells

  2019cites this paper
• Targeting Hsp-90 Related Disease Entities for Therapeutic Development

  2019cites this paper
• Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

  2019cites this paper
• Post-Translational Modifications in NETosis and NETs-Mediated Diseases

  2019cites this paper
• The application of the improved 3 D rat testicular cells co-culture model on the in vitro toxicity research of HZ 1006

  2018cites this paper
• Optogenetics in cancer drug discovery

  2018cites this paper
• Histone deacetylase inhibitors suppress transdifferentiation of gonadotrophs to prolactin cells and proliferation of prolactin cells induced by diethylstilbestrol in male mouse pituitary

  2018cites this paper
• Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis

  2017cites this paper
• Acetylation of α-tubulin by a Histone Deacetylase Inhibitor, Resminostat, Leads Synergistic Antitumor Effect with Docetaxel in Non-Small Cell Lung Cancer Models

  2017cites this paper
• LSD 1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP BENNESCH

  2017cites this paper
• In focus in HCB

  2017cites this paper
• Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation

  2017cites this paper
• Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker

  2017cites this paper
• Elevation of YAP promotes the epithelial‐mesenchymal transition and tumor aggressiveness in colorectal cancer

  2017cites this paper
• Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats

  2016cites this paper
• Novel Approaches to Endocrine Therapy in Endocrine-Independent Breast Cancer

  2016cites this paper
• Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells

  2016cites this paper
• LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP

  2016cites this paper
• HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

  2016cites this paper
• Breast Cancer: Molecular Mechanisms, Diagnosis, and Treatment

  2015cites this paper
• The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies

  2015cites this paper
• Hsp90 as a therapeutic target in endocrinology: current evidence

  2015cites this paper
• Enhancement of stress resilience through histone deacetylase 6-mediated regulation of glucocorticoid receptor chaperone dynamics.

  2015cites this paper
• Covalent Enzyme Inhibitors in Drug Design

  2015cites this paper
• Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

  2015cites this paper
• A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

  2015cites this paper
• Studies on the role of two proteins in breast cancer - histone deacetylase 11 in estrogen receptor positive breast cancer and the redox protein memo in metastasis and tumorigenesis

  2015influential citation
• The potential of histone deacetylase inhibitors in breast cancer therapy

  2015cites this paper
• In vitro mechanism for down-regulation of ERalpha expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells

  2015cites this paper
• The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells

  2015cites this paper
• Enhancement of stress resilience through Hdac6-mediated regulation of glucocorticoid receptor chaperone dynamics

  2015cites this paper
• Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer

  2015cites this paper
• Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression

  2015cites this paper
• Epigenetics and Three Main Clinical Aspects of Breast Cancer Management

  2015cites this paper
• Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer

  2014cites this paper
• Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway

  2014cites this paper
• The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype.

  2014cites this paper
• Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling.

  2014cites this paper
• A Chimeric SERM–Histone Deacetylase Inhibitor Approach to Breast Cancer Therapy

  2014cites this paper
• Breast cancer: Current and future endocrine therapies

  2014cites this paper
• A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor.

  2014cites this paper
• The role of aryl hydrocarbon receptor-regulated cytochrome P450 enzymes in glioma.

  2013cites this paper
• In vitro mechanism for downregulation of ER-α expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells.

  2013cites this paper
• HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole-Resistant MCF-7Ca Xenografts to Aromatase Inhibitors through Modulation of Her-2

  2013cites this paper
• Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data

  2013cites this paper
• chaperone function in human leukemia cells HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90

  2013cites this paper
• Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt

  2013cites this paper
• A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

  2013cites this paper
• A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

  2013cites this paper
• Photoinduced DNA cleavage by anthracene based hydroxamic acids.

  2012cites this paper
• Signalisation par les récepteurs des œstrogènes : mécanismes de reconnaissance de l’ADN et nouvelles approches pharmacologiques d’inhibition

  2012cites this paper
• Structural characterization of tetranortriterpenes from Pseudrocedrela kotschyi and Trichilia emetica and study of their activity towards the chaperone Hsp90.

  2012cites this paper
• Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects

  2012cites this paper
• New drugs, old fashioned ways: ER stress induced cell death.

  2012cites this paper
• HDAC6 Regulates Glucocorticoid Receptor Signaling in Serotonin Pathways with Critical Impact on Stress Resilience

  2012cites this paper
• Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

  2012cites this paper
• The Role of Heat Shock Proteins in Mammary Neoplasms: A Brief Review

  2012cites this paper
• Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.

  2012cites this paper
• Regulation of the Timing of Puberty: Exploration of the Role of Epigenetics

  2012cites this paper
• Sensitization of tumor cells by targeting histone deacetylases.

  2012cites this paper
• 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.

  2012cites this paper
• Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

  2012cites this paper
• Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.

  2012cites this paper
• The effects of the histone deacetylase inhibitor, LBH589, on breast cancer in bone and on physiological bone remodelling.

  2012cites this paper
• HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.

  2012cites this paper
• Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system

  2012cites this paper
• The Potential of Epigenetic Compounds in Treating Diabetes

  2012cites this paper
• Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells

  2012cites this paper
• A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells

  2012cites this paper
• Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90

  2011cites this paper
• Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.

  2011cites this paper
• Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation

  2011cites this paper
• The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines

  2011cites this paper